Bristol-Myers Squibb Reports Better-than-Expected Q2 2026 Financials
Bristol-Myers Squibb (NYSE: BMY) reported stronger-than-expected financial results for the second quarter of fiscal year 2026, leading to a stock price increase. The company raised its full-year outlook due to strong performance from cancer therapies in its growth portfolio. Revenue reached approximately $13 billion for Q2 FY2026, reflecting about 6% year-over-year (YoY) growth. The positive results were driven by robust sales of key oncology products and continued momentum across the company's pipeline. Bristol-Myers is a major player in pharmaceutical innovation, particularly within cancer treatment development.
Tickers: $BMY
Topics: Cancer Therapies Financial Performance Pharmaceuticals